Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trialResearch in context

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trialResearch in context

Summary: Background: We assessed the safety and immunogenicity of a core–shell structured lipopolyplex (LPP) based COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults. Methods: We conducted an open-labeled, two-centered, and three-arm randomised phase 1 trial. Healthy adu...

Full description

Bibliographic Details
Main Authors: Yu-Zhou Gui, Xue-Ning Li, Jing-Xin Li, Ming-Yun Shen, Mei-Wei Zhang, Ye Cao, Hong-Rong Xu, Hui Li, Jie Cheng, Liang Pan, Ying-Lei Yi, Li-Yu Liang, Cheng-Yin Yu, Gang-Yi Liu, Chen Yu, Bi-Jie Hu, Feng-Cai Zhu, Fei Liang, Haifa Shen, Jing-Ying Jia, Hang-Wen Li, Jian Zhou, Jia Fan
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:EBioMedicine
Subjects:
SARS-CoV-2
Heterologous boosting
mRNA vaccine
Clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423001512

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423001512

Similar Items